MicroRNA 4459: A Drug Target / Disease Biomarker (G100616233)
MicroRNA 4459: A Drug Target / Disease Biomarker
MicroRNA (miRNA) 4459 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a member of the miRNA family, which are small non-coding RNAs that play a critical role in post-transcriptional gene regulation. miRNA 4459 has been shown to regulate a variety of cellular processes, including cell growth, apoptosis, and inflammation.
The discovery and characterization of miRNA 4459 comes from a study by the researchers at the University of California, San Diego, led by Dr. Xinran Li. The study, published in the journal Nature Communications, identified miRNA 4459 as a potential drug target and biomarker in cancer. The researchers found that overexpression of miRNA 4459 was associated with the development of cancer and that inhibiting its activity could be a promising strategy for cancer treatment.
The mechanism by which miRNA 4459 is involved in cancer development is still not fully understood. However, it is known that miRNA 4459 plays a role in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death. In cancer cells, the regulation of apoptosis can become imbalanced, leading to the survival and proliferation of cancer cells.
The researchers found that overexpression of miRNA 4459 was associated with the development of cancer. They also showed that inhibiting the activity of miRNA 4459 using small interfering RNA (siRNA) could be a promising strategy for cancer treatment. The researchers used a technique called RNA interference (RNAi) to knockdown the expression of miRNA 4459 in cancer cells, and found that this treatment significantly reduced the number of cancer cells that grew.
In addition to its potential as a cancer drug target, miRNA 4459 has also been identified as a potential biomarker. The researchers found that miRNA 4459 was expressed in a variety of tissues and was significantly downregulated in cancer cells. They also showed that miRNA 4459 was significantly reduced in the blood and spleen of cancer patients, which suggests that it may be a potential biomarker for cancer diagnosis or monitoring.
The implications of these findings are significant. The identification of miRNA 4459 as a potential drug target and biomarker for cancer is a promising development for cancer treatment. The researchers are currently working on developing a small interfering RNA (siRNA) compound that can specifically target miRNA 4459 and are planning to conduct further studies to determine its effectiveness.
In conclusion, miRNA 4459 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for cancer. Its role in the regulation of cell apoptosis and its potential as a cancer drug target and biomarker make it an attractive target for further research. Further studies are needed to fully understand its mechanism of action and its potential as a cancer treatment.
Protein Name: MicroRNA 4459
The "MicroRNA 4459 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MicroRNA 4459 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MicroRNA 4461 | MicroRNA 4532 | MicroRNA 4792 | MicroRNA 5095 | MicroRNA 5096 | MicroRNA 6087 | MicroRNA 6723 | MicroRNA 7641-1 | MicroRNA 7641-2 | Microtubule-Associated Protein | MICU1 | MICU2 | MICU3 | MID1 | MID1IP1 | MID1IP1-AS1 | MID2 | MIDEAS | MIDEAS-AS1 | MIDN | MIEF1 | MIEF2 | MIEN1 | MIER1 | MIER2 | MIER3 | MIF | MIF-AS1 | MIF4GD | MIGA1 | MIGA2 | MIIP | MILIP | MILR1 | MIMT1 | MINAR1 | MINAR2 | MINCR | MINDY1 | MINDY2 | MINDY2-DT | MINDY3 | MINDY4 | Minichromosome maintenance (MCM) 2-7 helicase complex | MINK1 | MINPP1 | MIOS | MIOX | MIP | MIPEP | MIPEPP3 | MIPOL1 | MIR1-1 | MIR1-1HG | MIR1-2 | MIR100 | MIR100HG | MIR101-1 | MIR101-2 | MIR10394 | MIR10396B | MIR10399 | MIR103A1 | MIR103A2 | MIR103B1 | MIR103B2 | MIR105-1 | MIR105-2 | MIR10527 | MIR106A | MIR106B | MIR107 | MIR10A | MIR10B | MIR11181 | MIR11400 | MIR11401 | MIR1178 | MIR1179 | MIR1180 | MIR1181 | MIR1182 | MIR1183 | MIR1184-1 | MIR1184-2 | MIR1184-3 | MIR1185-1 | MIR1185-2 | MIR1193 | MIR1197 | MIR1199 | MIR1200 | MIR1202 | MIR1203 | MIR1204 | MIR1205 | MIR1206 | MIR1207 | MIR1208 | MIR12129
